Profund Advisors LLC Has $1.63 Million Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Profund Advisors LLC boosted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 86.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,465 shares of the company’s stock after purchasing an additional 43,692 shares during the period. Profund Advisors LLC owned about 0.06% of BridgeBio Pharma worth $1,625,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Clear Street Markets LLC acquired a new stake in BridgeBio Pharma in the first quarter valued at $33,000. Quantbot Technologies LP grew its holdings in BridgeBio Pharma by 500.0% during the 1st quarter. Quantbot Technologies LP now owns 4,200 shares of the company’s stock worth $42,000 after acquiring an additional 3,500 shares during the period. Sandia Investment Management LP acquired a new stake in BridgeBio Pharma during the 1st quarter worth about $83,000. Quantamental Technologies LLC bought a new position in shares of BridgeBio Pharma during the 1st quarter worth about $104,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of BridgeBio Pharma during the 3rd quarter worth about $105,000. 90.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $29.24 on Tuesday. BridgeBio Pharma, Inc. has a 52-week low of $6.64 and a 52-week high of $36.36. The company has a market capitalization of $5.09 billion, a P/E ratio of -7.50 and a beta of 1.00. The company has a fifty day moving average of $26.84 and a 200-day moving average of $23.97.

Analyst Ratings Changes

Several equities analysts recently weighed in on BBIO shares. Mizuho reaffirmed a “buy” rating and issued a $60.00 price target on shares of BridgeBio Pharma in a research report on Monday, August 28th. JPMorgan Chase & Co. cut their price target on shares of BridgeBio Pharma from $42.00 to $38.00 and set an “overweight” rating for the company in a report on Thursday, August 17th. Cantor Fitzgerald started coverage on shares of BridgeBio Pharma in a report on Tuesday, October 24th. They issued an “overweight” rating and a $50.00 price target for the company. Finally, Citigroup started coverage on shares of BridgeBio Pharma in a report on Tuesday, November 7th. They issued a “buy” rating and a $42.00 price target for the company. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average target price of $38.75.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.